Anavex Life Sciences Corp. AVXL
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 7.82M | -5.34M | -5.68M | -9.83M | -13.24M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.08M | 314.00K | 1.11M | 3.72M | 4.32M |
| Change in Net Operating Assets | 164.00K | 584.00K | -2.58M | -2.50M | -3.55M |
| Cash from Operations | -9.10M | -4.44M | -7.15M | -8.60M | -12.46M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 113.00K | 36.32M | 10.46M | 119.00K |
| Repurchase of Common Stock | -- | -- | -- | -445.00K | -2.26M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 113.00K | 36.32M | 10.02M | -2.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.10M | -4.33M | 29.17M | 1.41M | -14.61M |